TABLE 1.

Autologous and heterologous complement-mediated lysis activities during passive immunization against autologous pretreatment virus isolates^a

Patient	Infection phase	Viremia control	% Autologous virolysis [%]				% Heterologous JR-FL virolysis
			Preb	Wk 0c	Wk 12d	Wk 24e	Preb	Wk 0c	Wk 12d	Wk 24e
NAB 01	Chronic	No	71.2	83.8	89.6	87.6	6.5	9.8	43.3	35.2
NAB 02	Chronic	No	54.3	40.3	52.9	24.9	18.2	−7.9	49.7	36.3
NAB 03	Chronic	Yes	36.5	31.8	77.3	56.8	40.7	40.7	48.1	65.0
NAB 04	Chronic	Yes	16.1	18.3	44.7	27.6	68.6	63.7	73.3	72.4
NAB 05	Chronic	No	65.6	59.8	71.7	67.0	61.9	42.3	56.4	50.5
NAB 06f	Chronic	No	87.4	83.6	ND	NA	ND	ND	ND	NA
NAB 07	Chronic	No	34.9	35.8	78.9	45.4	10.2	−0.3	47.3	25.4
NAB 08	Acute	Yes	29.3	18.1	75.7	52.7	38.2	17.2	44.3	54.8
NAB 09	Chronic	No	49.7	52.6	71.6	40.6	41.8	38.9	68.4	48.8
NAB 10	Acute	No	5.8	5.3	45.1	46.2	−0.6	−27.4	56.6	36.6
NAB 11	Acute	No	9.9	18.7	59.5	58.6	51.7	49.3	50.7	68.9
NAB 12	Acute	Yes	−3.1	19.6	60.9	56.8	4.3	25.0	39.9	47.2
NAB 13	Acute	Yes	10.1	30.1	46.1	50.7	0.0	−4.9	13.7	21.6
NAB 14	Acute	Yes	48.1	53.4	55.3	37.1	56.4	38.2	18.7	26.4

^aMeans (95% confidence intervals) from the multivariable linear regression model were 39.4% (24.9% to 53.8%) at week 0, 63.8% (54.8% to 72.8%) at week 12, and 50.2% (40.0% to 60.3%) for autologous virolysis and 21.9% (5.3% to 38.4%) at week 0, 47.0% (36.6% to 57.3%) at week 12, and 45.3% (34.9% to 55.7%) at week 24 for heterologous virolysis (see Table S2 in the supplemental material). NA, not applicable; ND, not done.

^bBefore last ART.

^cBefore antibody infusion.

^dAt highest antibody trough level.

^eAfter wash-out of the antibodies.

^fPatient NAB 06 stopped the passive immunization study after week 12 and went back on ART.